ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2026
Essence of toxicology research to Saudi Arabia Vision 2030 and beyond: Current state and future perspectives.
Article in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Kingdom of Saudi Arabia has been making significant progress as part of its Vision 2030 to diversify its economy and reduce dependence on fossil fuels. Key components of this transformation include the development of a robust research and development (R&D) ecosystem and biotechnology-based industry. The Kingdom has recently formed the Research, Development and Innovation Authority (RDIA) to regulate and fund research with Health and Wellness being among its top priorities, and the Saudi National Institute of Health (SNIH) to support translational health research and clinical trials. In addition, the country has launched its National Biotechnology Strategy with a bold goal of becoming a biotechnology hub in the region by 2030 and globally by 2040. Toxicology research is central to these transformations. Historically, it has served as a cornerstone to biomedical and healthcare R&D. Today, with advancements in materials science and the integration of multiple technologies (e.g., biotechnology, nanotechnology, artificial intelligence, etc.) across the different industry sectors, it has become more critical than ever to assess safety early in the development process. In this editorial, we discuss the essence of toxicology research in realizing the country's ambitious goals of Vision 2030 and beyond, particularly in the development of the healthcare and biomedical R&D sectors and advancing a biotechnology-based industry. We first provide an overview of the current state of toxicology research and discuss its critical role in advancing the goals of Vision 2030. Finally, we discuss future directions for harnessing toxicology research towards achieving the country's ambitious goals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.